Blue Shield of California has received a contract to provide Agendia's MammaPrint and other tests in-network coverage across the US.
The FDA cleared MammaPrint gene expression signature assay is a prognostic and predictive tool designed to identify patients whose risk of metastases is high, requiring chemotherapy, and those at a low risk of metastases, who can be treated just as effectively with other therapies.
Agendia will be reimbursed for its MammaPrint test at an in-network rate, as a result of the contract.
In addition to Blue Shield of California , Agendia has also entered contracts with Palmetto, Humana, Coventry and several national PPO plans.